ZEVRA THERAPEUTICS, INC. (ZVRA) - Dilution Analysis

10-Q filing | 58.4M shares outstanding

10-K filing | 57.3M shares outstanding

10-Q filing | 56.0M shares outstanding

10-Q filing | 56.3M shares outstanding

10-Q filing | 54.1M shares outstanding

10-K filing | 53.7M shares outstanding

10-Q filing | 53.2M shares outstanding

10-Q filing | 41.9M shares outstanding

S-3 filing: The company may offer up to $350,000,000 of any combination of common stock, preferred stock, debt securities and warrants in one or more offerings.

10-Q filing | 41.8M shares outstanding

10-K filing | 41.5M shares outstanding

S-3 filing: The filing relates to the offer and resale of up to 2,269,721 shares of common stock by selling stockholders.

10-Q filing | 34.7M shares outstanding

10-Q filing | 33.9M shares outstanding

10-Q filing | 34.5M shares outstanding

10-K filing | 34.5M shares outstanding

10-Q filing | 34.5M shares outstanding

10-Q filing | 34.4M shares outstanding

10-Q filing | 34.5M shares outstanding

10-K filing | 35.0M shares outstanding

POS AM filing: This prospectus relates to the issuance of up to 1,366,184 shares of our common stock issuable upon the exercise of the outstanding Warrants, at an exercise price of $6.50 per share, and the issuance of up to 425,634 shares of common stock issuable upon the exercise of the outstanding Underwriter Warrants, at an exercise price of $8.125.

10-Q filing | 35.2M shares outstanding

10-Q filing | 35.0M shares outstanding

S-3 filing: The filing is an S-3 form registering securities for sale, including common stock, preferred stock, and debt securities, with a total offering amount of $350,000,000. The company may offer securities from time to time.

S-3 filing: This S-3 filing registers 1,529,379 shares of common stock issuable upon exercise of outstanding warrants for resale by selling stockholders.

10-Q filing | 28.5M shares outstanding

10-K filing | 28.4M shares outstanding

S-3 filing: The filing covers the offer and resale of up to 7,944,430 shares of common stock issuable upon exercise of outstanding warrants.

8-K filing: The Company completed a warrant exchange and inducement transaction where holders exercised warrants to purchase 6,620,358 shares of common stock for cash, and the Company issued new warrants to purchase up to 7,944,430 shares, receiving gross proceeds of approximately $44.0 million. ($44.0M proceeds)

8-K filing: KemPharm, Inc. consummated an underwritten public offering of 6,765,463 shares of common stock and issued inducement warrants to purchase up to 7,944,430 shares in exchange for the exercise of existing warrants, with expected gross proceeds of approximately $44.0 million. ($44.0M proceeds)

S-3 filing: This prospectus covers the offer and resale by the selling stockholders identified in this prospectus of up to an aggregate of 8,474,709 shares of our common stock issuable upon exercise of outstanding warrants to purchase 3,632,019 shares of our common stock, or the Warrants, and upon conversion of 31,476.98412 shares of our Series B-2 convertible preferred stock.

S-1/A filing: The company is offering 4,784,688 shares of its common stock and warrants to purchase up to 4,784,688 shares of its common stock along with pre-funded warrants.

S-1/A filing: The company is offering 4,340,277 shares of its common stock and warrants to purchase up to 4,340,277 shares of its common stock, as well as pre-funded warrants, with an assumed combined public offering price of $11.52 per share and accompanying warrant.

8-K filing: Stock split 1-for-16 | Outstanding: 72,514,304 → 4,532,144

S-1/A filing: The company is offering 46,991,521 shares of common stock and warrants to purchase up to 46,991,521 shares of common stock, as well as pre-funded warrants to purchase shares of common stock. The combined public offering price is $0.9789 per share of common stock and accompanying warrant.

S-1 filing: The company is filing an S-1 to offer common stock and warrants.

10-Q filing | 70.8M shares outstanding

10-Q filing | 72.5M shares outstanding

10-Q filing | 65.8M shares outstanding

S-3/A filing: The filing is an S-3/A registration statement for the potential offering of common stock, preferred stock, and debt securities up to an aggregate amount of $80,000,000, including an equity line with Lincoln Park.

10-K filing | 50.7M shares outstanding

8-K filing: KemPharm, Inc. issued a total of 3,000,000 shares of its common stock in exchange for convertible promissory notes totaling $1,800,000 between January 2, 2020, and January 7, 2020. ($1.8M proceeds)

8-K filing: KemPharm, Inc. issued a total of 3,112,333 shares of common stock in three separate unregistered transactions: 1,112,333 shares upon conversion of Series A convertible preferred stock on December 18, 2019, and 1,000,000 shares each on December 26 and December 30, 2019, upon exchange of convertible promissory notes.